$24.50
▼ $-0.60
(-2.39%)
Vol 2.0M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.1B
ROE
-84.9%
D/E
0.00
Beta
0.55
52W
$13–$28
Wall Street Consensus
24 analysts · Apr 20269
Strong Buy
9
Buy
6
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.73 | $-0.61 | +$0.12 |
| Sep 2025 | $-0.73 | $-0.73 | +$0.00 |
| Jun 2025 | $-0.66 | $-0.71 | $-0.05 |
| Mar 2025 | $-0.73 | $-0.64 | +$0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$111.1M | -$106.4M | -$120.6M | -$126.5M | -$110.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -84.4% | -80.6% | -84.5% | -84.5% | -84.9% | -84.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 12.32 | 11.16 | 12.32 | 12.32 | 9.07 | 9.07 |
Key Ratios
ROA (TTM)
-76.1%
P/B
4.1
EPS (TTM)
$-2.83
CF/Share
$-1.96
52W High
$27.69
52W Low
$12.72
$12.72
52-Week Range
$27.69
Financial Health
Free Cash Flow
-$92.3M
Cash
$994.5M
As of Dec 31, 2025
How does IMVT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IMVT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
4.1
▲
67%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IMVT profitability vs Biotechnology peers
ROE
-84.9%
▼
26%
below
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-76.1%
▼
63%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
IMVT financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
9.1
▲
104%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.6
▼
43%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IMVT fundamentals radar
IMVT
Peer median
Industry
IMVT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IMVT vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
VAN TUYL CHRISTOPHER
Officer · Mar 18
2877 shs
GLORIA MELANIE
Chief Operating Officer · Feb 25
3238 shs
STOUT JAY S
Chief Technology Officer · Jan 21
1977 shs
STOUT JAY S
Chief Technology Officer · Jan 07
1203 shs
Last 90 days
Top Holders
Top 5: 23.63%FMR, LLC
8.35%
$408.5M
Deep Track Capital, Lp
5.66%
$277.1M
Vanguard Group Inc
3.82%
$187.0M
Blackrock Inc.
2.98%
$145.6M
Armistice Capital, LLC
2.82%
$138.2M
As of Dec 31, 2025